New Imaging Test May Make Finding Recurrent Prostate Cancer Easier

Posted by The Prostate Seed Institute on August 16th, 2017

The American Cancer Society projects that 161,000 men across the country will receive a diagnosis of prostate cancer in the coming year. While some of these men may choose a path of surveillance rather than direct intervention, others will find more aggressive treatment is recommended in their cases. Up to a third of men in the latter group are likely to find their cancer returns even after treatment. A new imaging technique, however, may hold the key to finding recurrences faster and pinpointing their locations.

The test under development involves the use of positron emission tomography and an imaging agent known as Axumin. The agent and PET scan are intended for use when routine prostate-specific antigen test results following treatment remain elevated. Elevations after treatment may signal prostate cancer recurrence.

In a recent study, Axumin was shown to have an overall detection rate of just under 68 percent. The contrast agent when used with a PET scan was able to detect localized and distant recurrences over a range of different PSA values. In addition, the tracer was found to be well-tolerated by patients it was used on. The study in question involved nearly 600 patients from clinical sites in several countries across the globe. Overall, the results were quite positive for the tracer’s ability to confirm and pinpoint recurrence location. The detection rate was highest for new tumors in the prostate/pelvic lymph node region than locations outside the pelvis, however.

Although more testing is required before Axumin might be available for widespread use, clinicians say the findings so far are encouraging. They are also important. Recurrences happen in about a third of all treated cases. Having the ability to confirm recurrence suspicions quickly while also being able to determine the extent and location of new tumors could have big implications for patient management, treatment and outcomes, researchers say. Precise information is especially important in cancer recurrences when tumors may be more resistant to conventional treatments. What’s more, current imaging tools don’t offer the sensitivity the new test provides, making it difficult to identify sites of recurrence.

Men who are treated for prostate cancer are urged to work with their doctors for any necessary follow-ups. Elevated PSA levels after treatment may signal a return of cancer. Early intervention in recurrences can greatly improve the odds of a positive outcome. Since all men are at risk for prostate cancer as they age, it is also recommended that men talk to their doctors about the need for routine screening for this often highly treatable condition.

About Author

Dr. Echt and his team at the Prostate Seed Institute offer the most highly sophisticated methods of radiation therapy available in the United States, equal to that found in major medical center and academic settings. These include prostate seed implantation, high dose radiation implants, and external beam radiation with image-guided and intensity-modulated (IGRT and IMRT) capabilities.